3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Squamous Cell Carcinoma of Head and Neck
4
Melanoma
3
Nasopharyngeal Carcinoma
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Vascular Complications
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumor
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Oropharyngeal Neoplasms
1
Oligoprogressive
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Mouth Neoplasms
1
Meningeal Carcinomatosis
1
Lung Neoplasms
1
Locally Advanced Rectal Cancer
1
Immune-Related Adverse Events
1
Glioma
1
Esophageal Squamous Cell Carcinoma
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Cancer Metastatic
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Interventions
Cyclophosphamide
25
fludarabine
19
Dexamethasone
17
pembrolizumab
13
Rituximab
12
venetoclax
9
Lenalidomide
9
Gemcitabine
9
Etoposide
9
pomalidomide
8
Vincristine
7
glofitamab
6
fludarabine phosphate
6
carfilzomib
6
Temozolomide
6
obinutuzumab
5
daratumumab
5
Prednisone
5
Nivolumab
5
Doxorubicin
5
Cisplatin
5
Calcium Dobesilate
5
Bortezomib
5
zanubrutinib
4
selinexor
4
Immunotherapy, Adoptive
4
Cytarabine
4
Carboplatin
4
Azacitidine
4
ruxolitinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
Immune Checkpoint Inhibitors
×
90 days
×
Clear all
No trials found.